Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Clearance Index as an outcome to detect efficacy of aztreonam lysine inhalation in cystic fibrosis
2013-004295-35Phase 4Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Apr 2014
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of aztreonam in cystic fibrosis (CF) and Pseudomonal infection (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: relative change in lung clearance index after treatment with AZLI and after standard therapy. Started Apr 2014; status: completed.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2013-004295-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004295-35.